ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

LID Lidco Group Plc

11.75
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Lidco Group Plc LSE:LID London Ordinary Share GB0030546849 ORD 0.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 11.75 11.50 12.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

LiDCO Group Plc Capital Markets Day & US progress update (1984O)

16/05/2018 7:00am

UK Regulatory


Lidco (LSE:LID)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Lidco Charts.

TIDMLID

RNS Number : 1984O

LiDCO Group Plc

16 May 2018

LiDCO Group Plc

("LiDCO" or the "Company")

Capital Markets Day & US progress update

Two new US HUP contract wins

LiDCO (AIM: LID), the hemodynamic monitoring company, is hosting a Capital Markets Day for investors today at its HQ London 16 Orsman Road, London, N1 5QJ. The presentations will be available later today on the Company's website http://www.lidco.com/investors/presentations/. Except as set out below, no new material price sensitive information will be provided.

Ahead of the Capital Markets Day today LiDCO provides the following update on US progress. The Company has had further success contracting two additional customers to its recently launched differentiated High Usage Programme (HUP) business model. HUP is building momentum after its launch in July 2017, and to date the Company now has four significant US customers.

The two latest customers to sign multi-year contracts are a Level 1 trauma centre in New York and a 1000+ bed hospital in the Mid-West. Whilst the initial orders are for eight monitors in total, the Company expects this to grow significantly as the two hospitals fully recognise the benefits of its technology and the unlimited use programme. Both of these customers have the scope to become substantial contracts over their term. This brings the total number of HUP monitors in the US to 66 units.

If you haven't already registered and would like to attend today please register with Walbrook PR on the number below or email lidco@walbrookpr.com

Commenting on the US progress, Matt Sassone, Chief Executive Officer of LiDCO, said: "HUP is having a transformational impact on our US sales and even with the initial success that we have had so far, year to date recurring revenues are up 95% in local currency versus prior year. We continue to be encouraged by the positive response to our HUP offering. The pipeline of opportunities continues to increase and as we accelerate the speed of conversion of other prospects in this large and growing market, we are confident that we can take further market share."

This announcement contains inside information as defined in Article 7 of the Market Abuse Regulation No. 596/2014 ("MAR").

For further information, please contact:

 
 LiDCO Group Plc                                                     www.lidco.com 
 Matt Sassone (CEO)                                       Tel: +44 (0)20 7749 1500 
  Jill McGregor (CFO) 
 
 finnCap                                                  Tel: +44 (0)20 7600 1658 
 Geoff Nash / Emily Watts (Corporate 
  Finance) 
 Stephen Norcross (Corporate Broking) 
 
 Walbrook PR Ltd                        Tel: 020 7933 8780 or lidco@walbrookpr.com 
 Paul McManus                                                   Mob: 07980 541 893 
 Lianne Cawthorne                                               Mob: 07584 391 303 
 

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, originally developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOunity: a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring. Version 2 of this software is only available on a new slim widescreen monitor and includes the optional high usage program software in selected markets.

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness.

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:

-- early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

-- quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time

The software incorporated into LiDCOrapid allows the LiDCOrapid monitor to co-display Medtronic's level of consciousness parameter ('BIS(TM') )* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors.

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

*BIS(TM) and Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.

**CNAP(TM) is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's headquarters are in London and its shares are traded on AIM.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCVELFFVEFEBBQ

(END) Dow Jones Newswires

May 16, 2018 02:00 ET (06:00 GMT)

1 Year Lidco Chart

1 Year Lidco Chart

1 Month Lidco Chart

1 Month Lidco Chart

Your Recent History

Delayed Upgrade Clock